Impact of HADS Anxiety and Depression Scores on the Efficacy of Dietary Interventions for Irritable Bowel Syndrome

Overview

Journal Aliment Pharmacol Ther

Specialties Gastroenterology
Pharmacology

Date 2024 Oct 11

PMID 39392338

Authors

Anthony OConnor

Sarah Gill

Elaine Neary

Sarah White

Alexander C Ford

Affiliations

Soon will be listed here.

Abstract

Background: Anxiety and depression are associated strongly with irritable bowel syndrome (IBS). Dietary therapies are used increasingly in the management of IBS, but the impact of common mental disorders on response to these has not been well studied.

Aims: To examine whether symptoms compatible with common mental disorders influence response to dietary interventions.

Methods: Prospective cohort study of adults, with either diarrhoea-predominant or mixed bowel habits, IBS Severity Scoring System [IBS-SSS] score ≥ 75 points. Participants completed the Hospital Anxiety and Depression score (HADS) and attended initially for British Dietary Association advice for IBS. IBS-SSS was re-checked 3 months later to assess response. If primary endpoint (≥ 50 point decrease in IBS-SSS) was not achieved, patients were offered low fermentable oligo-, di- and monosaccharides and polyol diet and repeated IBS-SSS after another 3 months. Secondary endpoints included of change in IBS-SSS and effect of symptom severity on response.

Results: In total, 448 patients took part, average age of 42 years and 79.0% were female. 69.9% of participants had HADS-A scores ≥ 8 and 39.3% with HADS-D scores ≥ 8. Average IBS-SSS score at baseline was 290 (SD 86). No significant difference was noted in achievement of the primary endpoint according to HADS-A scores (53.4% vs. 62.2% by ITT in those with HADS-A ≥ 8 vs. HADS-A < 8, p = 0.09). Patients with HADS-D ≥ 8 were significantly less likely to achieve the primary endpoint compared with those with HADS-D < 8 (43.8% vs. 64.0% by ITT, p < 0.01).

Conclusion: Understanding psychological profile of patients can help predicting their response to IBS dietary interventions.

References

Black C, Thakur E, Houghton L, Quigley E, Moayyedi P, Ford A . Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2020; 69(8):1441-1451. DOI: 10.1136/gutjnl-2020-321191. View

Spiegel B, Camilleri M, Bolus R, Andresen V, Chey W, Fehnel S . Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report. Gastroenterology. 2009; 137(6):1944-53.e1-3. PMC: 2793276. DOI: 10.1053/j.gastro.2009.08.047. View

Oka P, Parr H, Barberio B, Black C, Savarino E, Ford A . Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5(10):908-917. DOI: 10.1016/S2468-1253(20)30217-X. View

Ford A, Wright-Hughes A, Alderson S, Ow P, Ridd M, Foy R . Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 402(10414):1773-1785. DOI: 10.1016/S0140-6736(23)01523-4. View

Staudacher H, Mahoney S, Canale K, Opie R, Loughman A, So D . Clinical trial: A Mediterranean diet is feasible and improves gastrointestinal and psychological symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2023; 59(4):492-503. DOI: 10.1111/apt.17791. View

Stasi C, Rosselli M, Bellini M, Laffi G, Milani S . Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol. 2012; 47(11):1177-85. DOI: 10.1007/s00535-012-0627-7. View

Zigmond A, SNAITH R . The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67(6):361-70. DOI: 10.1111/j.1600-0447.1983.tb09716.x. View

van Tilburg M, Palsson O, Whitehead W . Which psychological factors exacerbate irritable bowel syndrome? Development of a comprehensive model. J Psychosom Res. 2013; 74(6):486-92. PMC: 3673027. DOI: 10.1016/j.jpsychores.2013.03.004. View

Drossman D, Toner B, Whitehead W, Diamant N, Dalton C, Duncan S . Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003; 125(1):19-31. DOI: 10.1016/s0016-5085(03)00669-3. View

10.

Boeckxstaens G, Drug V, Dumitrascu D, Farmer A, Hammer J, Hausken T . Phenotyping of subjects for large scale studies on patients with IBS. Neurogastroenterol Motil. 2016; 28(8):1134-47. DOI: 10.1111/nmo.12886. View

11.

Black C, Staudacher H, Ford A . Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2021; 71(6):1117-1126. DOI: 10.1136/gutjnl-2021-325214. View

12.

Kronish I, Rieckmann N, Halm E, Shimbo D, Vorchheimer D, Haas D . Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes. J Gen Intern Med. 2006; 21(11):1178-83. PMC: 1831650. DOI: 10.1111/j.1525-1497.2006.00586.x. View

13.

Ford A, Talley N, Spiegel B, Foxx-Orenstein A, Schiller L, Quigley E . Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008; 337:a2313. PMC: 2583392. DOI: 10.1136/bmj.a2313. View

14.

Koloski N, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley N . The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut. 2012; 61(9):1284-90. DOI: 10.1136/gutjnl-2011-300474. View

15.

Jones M, Tack J, Van Oudenhove L, Walker M, Holtmann G, Koloski N . Mood and Anxiety Disorders Precede Development of Functional Gastrointestinal Disorders in Patients but Not in the Population. Clin Gastroenterol Hepatol. 2017; 15(7):1014-1020.e4. DOI: 10.1016/j.cgh.2016.12.032. View

16.

. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021; 398(10312):1700-1712. PMC: 8500697. DOI: 10.1016/S0140-6736(21)02143-7. View

17.

Koloski N, Jones M, Walker M, Veysey M, Zala A, Keely S . Population based study: atopy and autoimmune diseases are associated with functional dyspepsia and irritable bowel syndrome, independent of psychological distress. Aliment Pharmacol Ther. 2019; 49(5):546-555. DOI: 10.1111/apt.15120. View

18.

Koloski N, Boyce P, Talley N . Somatization an independent psychosocial risk factor for irritable bowel syndrome but not dyspepsia: a population-based study. Eur J Gastroenterol Hepatol. 2006; 18(10):1101-9. DOI: 10.1097/01.meg.0000231755.42963.c6. View

19.

Francis C, Morris J, Whorwell P . The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997; 11(2):395-402. DOI: 10.1046/j.1365-2036.1997.142318000.x. View

20.

Zamani M, Alizadeh-Tabari S, Zamani V . Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2019; 50(2):132-143. DOI: 10.1111/apt.15325. View